Abstract
Sporadic colorectal cancer (sCRC) is one of the most frequent types of cancer in Europe. Despite understanding of its tumorigenesis, the metastatic process is not yet clear. In this article, we review the most significant genetic and proteomic advances that have been made in regards to research of the sCRC metastatic process, and the new biomarkers that are able to predict disease prognosis or response to treatments, in order to define personalized medicine.
- Received May 20, 2012.
- Revision received October 23, 2012.
- Accepted October 29, 2012.
- Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved
In this issue
Jump to section
- Article
- Abstract
- Genomic Alterations Involved in Liver Metastatic sCRC
- Proteomic Alterations Involved in Liver Metastatic sCRC
- Identification of Biomarkers in Metastatic sCRC
- Discovery of Biomarkers from Genomic Approaches
- Discovery of Biomarkers by Proteomic Approaches
- Future of Biomarkers for Metastatic sCRC
- Conflicts of Interest
- Acknowledgments
- References
- Figures & Data
- Info & Metrics